Edith Borcoman, Ana Lalanne, Jean-Pierre Delord, Philippe A Cassier, Frédéric Rolland, Sébastien Salas, Jean-Marc Limacher, Olivier Capitain, Olivier Lantz, Christina Ekwegbara, Emmanuelle Jeannot, Joanna Cyrta, Carine Tran-Perennou, Zahra Castel-Ajgal, Grégoire Marret, Eliane Piaggio, Maud Brandely, Annette Tavernaro, Hakim Makhloufi, Kaidre Bendjama, Christophe Le Tourneau
PURPOSE: To evaluate tipapkinogene sovacivec (TG4001), a viral immunotherapeutic vaccine expressing human papillomavirus (HPV)16 E6/E7 non-oncogenic proteins and IL-2, in combination with avelumab in HPV16+ cancer patients. PATIENTS AND METHODS: In this open-label, phase Ib/II, multicenter study, HPV16+ advanced cancer patients received subcutaneous TG4001 at two dose levels (DL) in phase Ib and at the recommended phase II dose (RP2D) in phase II weekly for 6 weeks, then every 2 weeks (q2Wk) until 6 months, thereafter every 12 weeks, in combination with avelumab q2Wk starting from day 8...
September 2023: European Journal of Cancer